Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma

por Ebert, Lisa M., Vandyke, Kate, Johan, M. Zahied, DeNichilo, Mark, Tan, Lih Y., Myo Min, Kay K., Weimann, Benjamin M., Ebert, Brenton W., Pitson, Stuart M., Zannettino, Andrew C. W., Wallington‐Beddoe, Craig T., Bonder, Claudine S.
Publicado 2021

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome

por Tan, Lih Yin, Mintoff, Chris, Johan, M. Zahied, Ebert, Brenton W., Fedele, Clare, Zhang, You Fang, Szeto, Pacman, Sheppard, Karen E., McArthur, Grant A., Foster-Smith, Erwin, Ruszkiewicz, Andrew, Brown, Michael P., Bonder, Claudine S., Shackleton, Mark, Ebert, Lisa M.
Publicado 2016

Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy

por Ebert, Lisa M, Yu, Wenbo, Gargett, Tessa, Toubia, John, Kollis, Paris M, Tea, Melinda N, Ebert, Brenton W, Bardy, Cedric, van den Hurk, Mark, Bonder, Claudine S, Manavis, Jim, Ensbey, Kathleen S, Oksdath Mansilla, Mariana, Scheer, Kaitlin G, Perrin, Sally L, Ormsby, Rebecca J, Poonnoose, Santosh, Koszyca, Barbara, Pitson, Stuart M, Day, Bryan W, Gomez, Guillermo A, Brown, Michael P
Publicado 2020